SKIP TO
CONTENT
Investigaton into Contaminated Fuel in Colorado
featured news
April 16, 2015
General
Off-Label Marketing Becomes Global Issue as World Health Organization Encourages Cost-Effectiveness
Amid global shortages of life-saving medical resources, the United Nations’ World Health Organization has released a report focusing on various cost-saving tactics for member nations to consider while strategizing medical policy. At the heart of the matter, the WHO found that most nations do not have procedures in place to […]
April 10, 2015
General
Millennium Pharmaceuticals Escapes False Claims Act Allegations; Judge Leaves First Amendment Arguments Intact
The ongoing off-label marketing debate has given rise to several False Claims Act lawsuits commenced by a single whistleblower. In a qui tam cause of action filed in November, 2009, whistleblower Frank Solis has alleged that Millennium Pharmaceuticals and Merck, Inc. engaged in the controversial sales technique known as off-label […]
October 14, 2014
General
Shire Pharmaceuticals to Pay $56 Million to Settle False Claims Act Allegations
According to a recent announcement by the Department of Justice, Shire Pharmaceuticals has agreed to pay $56 million to settle claims it fraudulently marketed the popular attention-deficit drug Adderall and thereafter submitted claims to U.S. government healthcare programs for reimbursement. The allegations differ from the oft-cited problem of “off-label marketing,” […]
August 8, 2014
General
Vascular Solutions to Pay $520,000 to Settle False Claims Act Allegations
In a recent False Claims Act settlement, Minneapolis-based Vascular Solutions, Inc. (“VSI”) has agreed to pay $520,000 to the federal government in order to settle claims it unlawfully marketed its products for the treatment of varicose veins. The company, which has admitted no liability or guilt in the matter, agreed […]
July 30, 2014
General
Off-Label Marketing Case Involving Calgene Survives Despite Defendants’ Motion to Dismiss
Earlier this month, a False Claims Act case against drug maker Calgene was unsealed, revealing allegations of off-label marketing with regard to its controversial cancer drug Thalomid. The case, in which the government opted not to intervene, has been subject to several months’ worth of procedural wrangling by both parties. […]
Contact UsFree Case Evaluation
"*" indicates required fields
By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.
featured investigations
$2.4B+
in 2025 post-trial judgments
$50B+
in Settlements & Verdicts
55+
Years of Experience With High-Profile Cases
100+
Attorneys Protecting Your Rights
20+
Years Ranked as Top Law Firm by Chambers USA
50
States in Which The Firm Has Successfully Litigated
On the Cutting Edge of the Profession
Legal Intelligencer